CTRI/2009/091/000638已完成1 期
Prospective, open-labeled, randomized, multi-centric clinical trial for Assessment of safety and efficacy of ReliDerm®M in the treatment of stable vitiligo
Reliance Life Sciences PvtLtd0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients of 12-50 years
- •2. Patients with minimum of 2 lesions at least 10 cm apart
- •3. Patient with patch size of 8-12 cm2
排除标准
- •1. Patients with history of bleeding diasthesis
- •2. Treatment with systemic corticosteroids or any other re-pigmentation therapy during the last 30 days prior to enrollment
- •3. Infection with Human Immunodeficiency Virus, Hepatitis B or Hepatitis C
- •4. Patients with known sensitivity to bovine serum
研究者
相似试验
进行中（未招募）
3 期
A clinical trial to study the effects of two drugs, R-TPR-007 and Norditropin® Nordilet® in growth hormone deficient childreCTRI/2015/06/005907Reliance Life Sciences Pvt Ltd
进行中（未招募）
不适用
Prospective, randomized, multi-center, open label phase III study to evaluate the efficacy and safety of immunosuppression following a heart-beating cadaveric renal transplantation based on the use of rabbit anti-T-lymphocyte serum, tacrolimus and mycophenolate, free of concomitant corticosteroids from the start of immunosuppression - IBERICArenal transplantationEUCTR2005-004431-21-PTFresenius Biotech GmbH160
招募中
不适用
Prospective, multicenter, randomized ,open-labeled, phase III study comparing high-dose intravenous methotrexate versus intrathecal methotrexate for the prophylaxis of CNS relapse in diffuse large B cell lymphomaKCT0003887Chonnam National University Hospital Hwasun Hospital205
Unknown
3 期
A clinical trial to study the effects of two drugs, R-TPR-033 and Erbitux® in patients with head and neck cancer of squamous cell type that has spread to other part of the bodyCTRI/2015/06/005909Reliance Life Sciences Pvt Ltd28
已完成
2 期
A open label, active control, phase 2 clinical study to evaluate immunogenicity, safety and tolerability of single heterologous booster dose of Protein Subunit Vaccine against SARS-CoV-2 Virus.CTRI/2023/09/057398Reliance Life Sciences Pvt Ltd RLS200